-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FqXtMsw5rIRIXLFuG1fHtmM+2EOYq6UAEC1mP9jL6aYvQz7WNtr1so8/quLpffJk 9Wr1dwQpN6QKTXeY2RhAUA== 0000891554-02-000078.txt : 20020413 0000891554-02-000078.hdr.sgml : 20020413 ACCESSION NUMBER: 0000891554-02-000078 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20020109 GROUP MEMBERS: AVENTIS HOLDINGS INC. GROUP MEMBERS: AVENTIS PHARMACEUTICALS INC. FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RHONE POULENC RORER INC CENTRAL INDEX KEY: 0000217028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 231699163 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 500 ARCOLA RD STREET 2: P O BOX 1200 M/S 5B14 CITY: COLLEGEVILLE STATE: PA ZIP: 19426-0107 BUSINESS PHONE: 6104548000 FORMER COMPANY: FORMER CONFORMED NAME: RORER AMCHEM INC DATE OF NAME CHANGE: 19770604 FORMER COMPANY: FORMER CONFORMED NAME: RORER GROUP INC DATE OF NAME CHANGE: 19900731 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INTROGEN THERAPEUTICS INC CENTRAL INDEX KEY: 0001018710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 742704230 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-61001 FILM NUMBER: 2505094 BUSINESS ADDRESS: STREET 1: 301 CONGRESS AVE STREET 2: SUITE 1850 CITY: AUSTIN STATE: TX ZIP: 78701 BUSINESS PHONE: 5127089310 MAIL ADDRESS: STREET 1: 301 CONGRESS AVE STREET 2: SUITE 1850 CITY: AUSTIN STATE: TX ZIP: 78701 SC 13D/A 1 d27640_sc13da.txt AMENDED GENERAL STATEMENT OF BENEFICIAL OWNERSHIP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INTROGEN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46119F 10 7 (CUSIP Number) Edward H. Stratemeier Vice President Rhone-Poulenc Rorer, Inc. 300 Somerset Corporate Boulevard Bridgewater, New Jersey 08807 908-243-6000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 31, 2001 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information that would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 CUSIP No. 46119F 10 7 - -------------------------------------------------------------------------------- 1) Name of Reporting Person: Aventis Pharmaceuticals Inc. I.R.S. Identification Nos. of Above Persons (entities only): 13-2563649 - -------------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ X ] - -------------------------------------------------------------------------------- 3) SEC Use Only - -------------------------------------------------------------------------------- 4) Source of Funds (See Instructions) WC - -------------------------------------------------------------------------------- 5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6) Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- 7) Sole Voting Power 2,343,721 (1) Number of ------------------------------------------------------------- Shares 8) Shared Voting Power Beneficially 0 Owned by ------------------------------------------------------------- Each 9) Sole Dispositive Power Reporting 2,343,721 (1) Person With ------------------------------------------------------------- 10) Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 11) Aggregate Amount Beneficially Owned by Each Reporting Person 2,343,721 - -------------------------------------------------------------------------------- 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - -------------------------------------------------------------------------------- 13) Percent of Class Represented by Amount in Row (11) 10.9% (2) - -------------------------------------------------------------------------------- 14) Type of Reporting Person (See Instructions) CO 2 - ---------------- (1) Represents 2,343,721 shares of common stock, par value $.001 per share (the "Common Stock") of Introgen Therapeutics, Inc. (the "Company") issuable upon conversion of Series A Non-Voting Convertible Preferred Stock of the Company that were acquired on July 2, 2001 by Aventis Pharmaceuticals Products Inc., which changed its name to Aventis Pharmaceuticals Inc. on December 31, 2001. (2) Beneficial ownership percentages set forth herein assume that at as of the date of this report, there were 21,442,382 shares of Common Stock outstanding. Pursuant to Rule 13d-3 under the Securities Exchange Act, as amended, 2,343,721 shares of Common Stock issuable upon conversion of the Introgen Series A Non-Voting Convertible Preferred Stock and deemed to be beneficially owned by the reporting person are also assumed to be outstanding for purposes of computing these percentages. 3 CUSIP No. 46119F 10 7 - -------------------------------------------------------------------------------- 1) Name of Reporting Person: Aventis Holdings Inc. I.R.S. Identification Nos. of Above Persons (entities only): 57-0414396 - -------------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ X ] - -------------------------------------------------------------------------------- 3) SEC Use Only - -------------------------------------------------------------------------------- 4) Source of Funds (See Instructions) AF - -------------------------------------------------------------------------------- 5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6) Citizenship or Place of Organization Delaware - -------------------------------------------------------------------------------- 7) Sole Voting Power 6,312,614 (1) Number of --------------------------------------------------------- Shares 8) Shared Voting Power Beneficially 0 Owned by --------------------------------------------------------- Each 9) Sole Dispositive Power Reporting 6,312,614 (1) Person With --------------------------------------------------------- 10) Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 11) Aggregate Amount Beneficially Owned by Each Reporting Person 6,312,614 - ----------------------------------------------------------------------------- 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - -------------------------------------------------------------------------------- 13) Percent of Class Represented by Amount in Row (11) 29.4% (2) - -------------------------------------------------------------------------------- 14) Type of Reporting Person (See Instructions) CO 4 - ---------------- (1) Represents direct ownership of 3,968,893 shares of Common Stock previously directly held by Rhone-Poulenc Rorer International (Holdings) Inc., and assigned to its affiliated company Aventis Holdings Inc. as part of a corporate restructuring, and beneficial ownership of the balance of the Subject Shares, which are directly held by Aventis Pharmaceuticals Inc., the equity of which is 100% owned by Aventis Holdings Inc., a Delaware corporation ("AHI"). (2) Beneficial ownership percentages set forth herein assume that at as of the date of this report, there were 21,442,382 shares of Common Stock outstanding. 5 CUSIP No. 46119F 10 7 - -------------------------------------------------------------------------------- 1) Name of Reporting Person: Rhone-Poulenc Rorer, Inc. I.R.S. Identification Nos. of Above Persons (entities only): 23-1699163 - -------------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ X ] - -------------------------------------------------------------------------------- 3) SEC Use Only - -------------------------------------------------------------------------------- 4) Source of Funds (See Instructions) Not Applicable - -------------------------------------------------------------------------------- 5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6) Citizenship or Place of Organization Pennsylvania - -------------------------------------------------------------------------------- 7) Sole Voting Power 6,312,614 (1) Number of --------------------------------------------------------- Shares 8) Shared Voting Power Beneficially 0 Owned by --------------------------------------------------------- Each 9) Sole Dispositive Power Reporting 6,312,614 (1) Person With --------------------------------------------------------- 10) Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 11) Aggregate Amount Beneficially Owned by Each Reporting Person 6,312,614 - -------------------------------------------------------------------------------- 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - -------------------------------------------------------------------------------- 13) Percent of Class Represented by Amount in Row (11) 29.4% (2) - -------------------------------------------------------------------------------- 14) Type of Reporting Person (See Instructions) CO 6 - ---------------- (1) Represents beneficial ownership of shares held directly by AHI, the equity of which is 100% owned by Rhone-Poulenc Rorer Inc., a Pennsylvania corporation ("RPR"), and by Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), the equity of which is 100% owned by AHI. (2) Beneficial ownership percentages set forth herein assume that at as of the date of this report, there were 21,442,382 shares of Common Stock outstanding. Pursuant to Rule 13d-3 under the Securities Exchange Act, as amended, 2,343,721 shares of Common Stock issuable upon conversion of the Introgen Series A Non-Voting Convertible Preferred Stock and deemed to be beneficially owned by the reporting person are also assumed to be outstanding for purposes of computing these percentages. 7 This Schedule 13D is filed to reflect the transfer of the shares of the Common Stock solely between affiliated companies as part of a corporate restructuring. The shares of Common Stock held by RPRIH were transferred to its affiliated entity, AHI. As a result of the transfer AHI and RPR, both of which are affiliated companies of API, and all of which are direct or indirect subsidiaries of Aventis SA, a French corporation, have acquired beneficial ownership of the Subject Shares. Also as part of this corporate restructuring APPI changed it name to Aventis Pharmaceuticals Inc. This Schedule 13D also is filed to incorporate Exhibits 99.1, 99.2 and 99.3, which were previously omitted. This Amendment amends Item 5 and Item 7 only. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. Item 5(b) is hereto amended and restated as follows: (b) The Reporting Entity, through its subsidiaries Aventis Holdings Inc. (with respect to the Original Introgen Shares) and Aventis Pharmaceuticals Inc. (with respect to the New Introgen Shares), has sole power to vote and to dispose of the Subject Shares subject, however, to the terms of the agreements referred to in and incorporated by reference into Item 4 above. Neither RPR, AHI nor API nor, to the knowledge of the Reporting Entity, any of the persons listed on Exhibits 99.1 or 99.2 hereto has any power to vote or to direct the vote, or to dispose of or to direct the disposition of, the Subject Shares except to the extent to the extent that any such person may be deemed to have any such power by reason of such person's relationship to or position with the Reporting Entity. 8 ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. 1 Series A Non-Voting Convertible Preferred Stock Purchase Agreement dated as of June 30, 2001. 2 Registration Rights Agreement dated as of June 30, 2001. 3 Voting Agreement dated as of June 30, 2001. 4 Series B Preferred Stock Purchase Agreement dated as of October 7, 1994, as amended by Series C Preferred Stock Purchase Agreement. 99.1 Information concerning directors and executive officers of API, AHI and RPR. 99.2 Information concerning members of the Supervisory Board and Management Board of Aventis SA. 99.3 Agreement to File Jointly dated January 9, 2002, by and among API, AHI and RPR. 9 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: January 9, 2001 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS HOLDINGS INC. Date: January 9, 2002 By: /s/Phillip R. Ridolfi Phillip R. Ridolfi President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. RHONE-POULENC RORER INC. Date: January 9, 2001 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President 10 INDEX OF EXHIBITS Exhibit Number Description ------ ----------- 1 Series A Non-Voting Convertible Preferred Stock Purchase Agreement dated as of June 30, 2001 (filed with Schedule 13D, which this Amendment amends). 2 Registration Rights Agreement dated as of June 30, 2001 (filed with Schedule 13D, which this Amendment amends). 3 Voting Agreement dated as of June 30, 2001 (filed with Schedule 13D, which this Amendment amends). 4 Series B Preferred Stock Purchase Agreement dated as of October 7, 1994, as amended by Series C Preferred Stock Purchase Agreement (incorporated by reference from Exhibits 10.33 and 10.5 to the Registration Statement on Form S-1 of the Company filed with the Securities and Exchange Commission (Registration No. 333-30582)). 99.1 Information concerning directors and executive officers of API, AHI and RPR (filed herewith). 99.2 Information concerning members of the Supervisory Board and Management Board of Aventis (filed herewith). 99.3 Agreement to File Jointly dated January 9, 2002, by and among API, AHI and RPR (filed herewith). EX-99.1 3 d27640_ex99-1.txt INFO. CON. DIRECTORS/EXECUTIVES OF API, AHI, RPR EXHIBIT 99.1 Directors and Officers of Aventis Pharmaceuticals Inc. , Aventis Holdings Inc. and Rhone-Poulenc Rorer Inc. The following sets forth the name, title, business address, and present principal occupation of each of the directors and executive officers of API as of January 9, 2002. All are citizens of the United States unless otherwise indicated in parentheses under his or her name. AVENTIS PHARMACEUTICALS INC.
Name Title Address Daniel Camus Chief Financial Officer Aventis Pharma AG1 (Germany) of Aventis Pharma AG 65926 Frankfurt Main and Director of API Germany Frank L. Douglas, Head of Research and Aventis Pharma AG Ph.D., M.D. Development of Aventis 65926 Frankfurt Main Pharma AG and Director Germany of API Richard J. Markham Chief Executive Officer Route 202-206 of Aventis Pharma AG Bridgewater, NJ 08807 and Director of API Thierry Soursac, Head of Commercial Route 202-206 M.D., Ph.D. Operations for Aventis Bridgewater, NJ 08807 Pharma AG and Director of API Gerald P. Belle President and Chief Executive 300 Somerset Corporate Blvd. Officer and Director of API Bridgewater, NJ 08807-0800 Susan Ketterman Vice President, NA 300 Somerset Corporate Blvd. Human Resources Bridgewater, NJ 08807-0800 John R. Leone Sr. Vice President, US 300 Somerset Corporate Blvd. Commercial Operations Bridgewater, NJ 08807-0800 Jurgen Lasowski Vice President, NA Business 300 Somerset Corporate Blvd. Development and Strategy, Bridgewater, NJ 08807-0800 Pierre Legault Vice President, Head of NA 300 Somerset Corporate Blvd. (Canada) Finance and Information Bridgewater, NJ 08807-0800 Systems and Chief Financial Officer Daniel G. Maher Vice President, Head of NA 10236 Marion Park Drive Industrial Operations Kansas City, MO 64137 Francois Nader, MD Vice President, Head of NA 300 Somerset Corporate Blvd. Medical Affairs/Regulatory Bridgewater, NJ 08807-0800 Charles F. Rouse, III Vice President, Head of NA 300 Somerset Corporate Blvd. Communications and Bridgewater, NJ 08807-0800 Community Affairs Mark R. Shaw Vice President, Head of NA 300 Somerset Corporate Blvd. Administrative Services Bridgewater, NJ 08807-0800
Edward H. Stratemeier Vice President, Head of NA 300 Somerset Corporate Blvd. Legal, Government Affairs Bridgewater, NJ 08807-0800 and Policy/Secretary Robert J. Carmody Vice President, North America 300 Somerset Corporate Blvd. Tax Bridgewater, NJ 08807-0800 Gerald Dahling Senior Vice President, Route 202-206 Global Patents Bridgewater, NJ 08807-0800 Charles D. Dalton Vice President, Legal Route 202-206 Corporate Development/ Bridgewater, NJ 08807-0800 Secretary Thomas Hofstaetter Senior Vice President, Route 202-206 Corporate Development Bridgewater, NJ 08807-0800 Claude Ourceyre Vice President, Corporate 300 Somerset Corporate Blvd. Human Resources - Bridgewater, NJ 08807-0800 Bridgewater Center Kirk Schueler Senior Vice President, Global Route 202-206 Marketing Bridgewater, NJ 08807-0800 Errol de Souza Vice President, Head of Route 202-206 DI&A U.S. Bridgewater, NJ 08807-0800 Michael A. Yeomans Vice President, Global Route 202-206 Business Development Bridgewater, NJ 08807-0800 Terry G. King Treasurer 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 AVENTIS HOLDINGS INC. Directors: - ---------- Pierre Legault Director 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Edward H. Stratemeier Director 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Robert J. Carmody Director 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Officers: - --------- Phillip R. Ridolfi President 3711 Kennett Pike, Suite 200 Greenville, DE 19807 Joan A. Hanlon Vice President & Treasurer 3711 Kennett Pike, Suite 200 Greenville, DE 19807 Andrea Q. Ryan Secretary 3711 Kennett Pike, Suite 200 Greenville, DE 19807 RHONE-POULENC RORER INC. Directors: - ---------- Pierre Legault Director 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800
Robert J. Carmody Director 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Officers: - --------- Pierre Legault President 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Charles D. Dalton Vice President Route 202-206 Bridgewater, NJ 08807-0800 Edward H. Stratemeier Vice President 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Robert J. Carmody Vice President/Asst. Treasurer 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Owen K. Ball, Jr. Secretary 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800 Terry G. King Treasurer 300 Somerset Corporate Blvd. Bridgewater, NJ 08807-0800
EX-99.2 4 d27640_ex99-2.txt INFO. CON. SUPERVISORY BOARD/MGMT OF AVENTIS Exhibit 99.2 Certain Information Relating to Directors and Executive Officers Supervisory Board and Board of Management and Executive Committee of Aventis SA Name and Business Address Principal Present Occupation - ------------------------- ---------------------------- SUPERVISORY BOARD Marc Vienot Chairman of the Supervisory Board of (France) Aventis Pharmaceuticals Societe Generale Tour Societe Generale F 92972 Paris la defense Cedex Dr. Martin Fruhauf Vice-Chairman of the Supervisory (Germany) Board of Aventis Aventis Gebaude K 801 Industriepark Hochst 65926 Frankfurt Jean-Marc Bruel Member of the Supervisory Board of (France) Aventis Aventis 46 quai de la Rapee 75601 Paris Cedex 12 Serge Kampf Member of the Supervisory Board of (France) Aventis CAP Gemini Sogeti 11, rue de Tilsit 75017 Paris Prof. Dr. Drs. h. c. Hubert Markl Member of the Supervisory Board of (Germany) Aventis Max-Planck-Geellschaft Hofgartenstrasse 8 80539 Munchen Dr. Gunter Metz Member of the Supervisory Board of (Germany) Aventis Celanese AG Frankfurter Str. 111 61476 Kronberg Didier Pineau-Valencienne Member of the Supervisory Board of (France) Aventis Schneider Electric 64 rue de Miromesnil 75008 Paris Seham Razzouqi Member of the Supervisory Board of (Kuwait) Aventis Kuwait Petroleum Corporation P.O. Box 26565 Safat 13126 Kuwait Michel Renault Member of the Supervisory Board (France) of Aventis ARJIL & Associes Banque 43 rue Vineuse 75116 Paris Dr. Hans-Jurgen Schinzler Member of the Supervisory Board of (Germany) Aventis Munchener Ruckversicherungs- Gesellschaft Koniginstrasse 107 80802 Munchen BOARD OF MANAGEMENT Jurgen Dormann Chairman of the Board of Management (Germany) of Aventis Aventis, 67917 Strasbourg, Cedex 9, France Jean-Rene Fourtou Vice-Chairman of the Board of (France) Management of Aventis Aventis, 67917 Strasbourg, Cedex 9, France Igor Landau Member of the Board of Management of (France) Aventis Aventis, 67917 Strasbourg, Cedex 9, France Horst Waesche Member of the Board of Management of (Germany) Aventis Aventis, 67917 Strasbourg, Cedex 9, France EXECUTIVE COMMITTEE Jurgen Dormann Chairman of the Board of Management of (Germany) Aventis Aventis, 67917 Strasbourg, Cedex 9, France Jean- Rene Fourtou Vice-Chairman of the Board of (France) Management of Aventis Aventis, 67917 Strasbourg, Cedex 9, France Alain Godard Chief Executive Officer of Aventis (France) Agriculture Igor Landau Member of the Board of Management of (France) Aventis Aventis, 67917 Strasbourg, Cedex 9, France Patrick Langlois Group Executive Vice President - (France) Chief Financial Officer Espace Europeen de l'Entreprise Avenue de l'Europe Schiltigheim France 67300 Richard J. Markham Chief Executive Officer of Aventis (United States) Pharma Route 202-206 Bridgewater, NJ 08807 Rene Penisson Group Executive Vice President - (France) Human Resources Espace Europeen de l'Entreprise Avenue de l'Europe Schiltigheim France 67300 Horst Waesche Member of the Board of Management of (Germany) Aventis Aventis, 67917 Strasbourg, Cedex 9, France EX-99.3 5 d27640_ex99-3.txt JOINT FILING AGREEMENT BY/AMONG API, AHI, RPR EXHIBIT 99.3 AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: January 9, 2002 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President AVENTIS HOLDINGS INC. Date: January 9, 2002 By: /s/Phillip R. Ridolfi Phillip R. Ridolfi President RHONE-POULENC RORER INC. Date: January 9, 2002 By: /s/Edward H. Stratemeier Edward H. Stratemeier Vice President -----END PRIVACY-ENHANCED MESSAGE-----